Figure S1. Tyrosine phosphorylation of CD95 is essential for increased cell killing by the combination of a MEK1/2 inhibitor and 17DMAG. HuH7 cells were transfected with plasmids to express GFP, GFP-CD95 or GFP-CD95 YY-FF. Twenty four h after transfection cells were treated with vehicle (DMSO) or the indicated concentrations of MEK1/2 inhibitor AZD6244 (6244, 100 nM) and/or 17DMAG (DMAG, 100 nM) and/or obatoclax (GX, 50 nM). Cells were isolated 24h after drug exposure and cell viability determined by trypan blue exclusion (n = 3 +/- SEM).

Figure S2. TRAIL enhances [MEK1/2 inhibitor + 17DMAG] toxicity to a greater extent than obatoclax. HuH7, HEPG2 and HEP3B cells were treated with vehicle (DMSO) or the indicated concentrations of MEK1/2 inhibitor (6244, 100 nM) and/or 17DMAG (DMAG, 100 nM) and/or TRAIL (5 ng/ml) and/or obatoclax (GX, 50 nM). Cells were isolated 24h after drug exposure and cell viability determined by trypan blue exclusion (n = 3 +/- SEM).

S1


Percentage cell death
100
80
60
40
20
0
VEH
DMAG
6244
DMAG+6244
VEH
DMAG+6244
VEH
GX
HuH7
HuH7
GFP
HuH7
CD95-GFP
HuH7
CD95 (mut)
-GFP

S2


Percentage cell death
100
80
60
40
20
0
21%
37%
40%
58%
60%
81%
VEH
DMAG
6244
DMAG+6244
VEH
GX
TRAIL
HuH7
HEP3B
HEPG2